Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjunctive pimavanserin for major depressive disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Adjunctive Treatment of Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-11-14